Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
Regeneron(REGN) stock is priced at $780.30, giving the company a market capitalization of 82.45B. It carries a P/E multiple of 18.94 and pays a dividend yield of 44.8%.
During the trading session on 2026-02-10, Regeneron(REGN) shares reached a daily high of $790.00 and a low of $775.52. At a current price of $780.30, the stock is +0.6% higher than the low and still -1.2% under the high.
Trading volume for Regeneron(REGN) stock has reached 569.39K, versus its average volume of 836.62K.
The stock's 52-week range extends from a low of $476.49 to a high of $821.11.
The stock's 52-week range extends from a low of $476.49 to a high of $821.11.
REGN News
Regeneron Pharmaceuticals has reported past full-year 2025 results showing modest revenue and net income growth, completed a US$1.51 billion share repurchase, a...
Guggenheim raised the firm’s price target on Regeneron (REGN) to $975 from $865 and keeps a Buy rating on the shares. The firm, which updated its model after ea...
Regeneron Pharmaceuticals (NasdaqGS:REGN) is presenting final long term Phase 3 data from its QUASAR and ELARA trials for EYLEA HD at a major ophthalmology conf...
Analyst ratings
72%
of 29 ratingsMore REGN News
Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals is launching a Phase 3 trial ti...
Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Regeneron’s latest update on its early-stage trial of REGN9533 marks an i...
AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...
Regeneron Pharmaceuticals (REGN) has disclosed a new risk, in the Technology category. Regeneron Pharmaceuticals faces growing exposure as it expands the use o...
Regeneron Pharmaceuticals (REGN) has just paired a Q4 2025 earnings beat with fresh momentum in its eye franchise, as new EYLEA HD data head to the Angiogenesis...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.